You are here

  • Home
  • Archive
  • Volume 47, Issue 4
  • Coexistence of two different pseudohypoparathyroidism subtypes (Ia and Ib) in the same kindred with independent Gsα coding mutations and GNAS imprinting defects

Article Text

Article menu
Download PDFPDF
Letter to JMG
Coexistence of two different pseudohypoparathyroidism subtypes (Ia and Ib) in the same kindred with independent Gsα coding mutations and GNAS imprinting defects
  1. B Lecumberri1,
  2. E Fernández-Rebollo2,3,
  3. L Sentchordi4,5,
  4. P Saavedra6,
  5. A Bernal-Chico2,
  6. L F Pallardo1,
  7. J M Jiménez Bustos4,
  8. L Castaño2,7,8,
  9. M de Santiago1,
  10. O Hiort9,
  11. G Pérez de Nanclares2,7,
  12. M Bastepe3
  1. 1Endocrinology Service, Hospital Universitario La Paz, Madrid, Spain
  2. 2Endocrinology and Diabetes Research Group, Molecular Genetics Laboratory, Hospital de Cruces, Barakaldo, Bizkaia, Spain
  3. 3Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
  4. 4Service of Pediatrics, Hospital Universitario de Guadalajara, Castilla La Mancha, Spain
  5. 5Service of Pediatrics, Hospital Infanta Leonor, Madrid, Spain
  6. 6Endocrinology Service, Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
  7. 7Centro de Investigación Biomédica en Red en Enfermedades Raras, Barakaldo, Bizkaia, Spain
  8. 8University of the Basque Country School of Medicine, Bilbao, Spain
  9. 9Department of Pediatric and Adolescent Medicine, University of Lübeck, Luebeck, Germany
  1. Correspondence to Guiomar Perez de Nanclares, Molecular Genetics Laboratory Research Unit, Hospital Txagorritxu, Vitoria-Gasteiz, E01009 Alava, Basque Country, Spain; gnanclares{at}osakidetza.net
  2. Murat Bastepe, Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Thier 10, Boston, Massachussetts 02114, USA; bastepe{at}helix.mgh.harvard.edu

Abstract

Background Pseudohypoparathyroidism (PHP) defines a rare group of disorders whose common feature is resistance to the parathyroid hormone. Patients with PHP-Ia display additional hormone resistance, Albright hereditary osteodystrophy (AHO) and reduced Gsα activity in easily accessible cells. This form of PHP is associated with heterozygous inactivating mutations in Gsα-coding exons of GNAS, an imprinted gene locus on chromosome 20q13.3. Patients with PHP-Ib typically have isolated parathyroid hormone resistance, lack AHO features and demonstrate normal erythrocyte Gsα activity. Instead of coding Gsα mutations, patients with PHP-Ib display imprinting defects of GNAS, caused, at least in some cases, by genetic mutations within or nearby this gene.

Patients Two unrelated PHP families, each of which includes at least one patient with a Gsα coding mutation and another with GNAS loss of imprinting, are reported here.

Results One of the patients with GNAS imprinting defects has paternal uniparental isodisomy of chromosome 20q, explaining the observed imprinting abnormalities. The identified Gsα coding mutations include a tetranucleotide deletion in exon 7, which is frequently found in PHP-Ia, and a novel single nucleotide change at the acceptor splice junction of intron 11.

Conclusions These molecular data reveal an interesting mixture, in the same family, of both genetic and epigenetic mutations of the same gene.

  • Pseudohypoparathyroidism
  • PHP-Ia
  • PHP-Ib
  • genetic mutations
  • imprinting defects
  • endocrinology
  • genetics

https://doi.org/10.1136/jmg.2009.071001

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • BL and EF-R contributed equally to this work.

    • Funding GPN is supported by Miguel Servet contracts from the Instituto de Salud Carlos III of the Spanish Ministry of Health (grant CP03/0064). This work was partially funded by grant GV2008/111035 from the Department of Health of the Basque Government and BIO08/ER/001. This group is also supported by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII. This work was also funded, in part, by grant number R01DK073911 from the National Institute of Diabetes and Digestive and Kidney Diseases (to MB) and from the German Ministry of Research and Education (GMG01GM0315 to OH). Other Funders: National Institutes of Health.

    • Competing interests None to declare.

    • Patient consent Obtained

    • Ethics approval This study was conducted with the approval of the Hospital de Cruces Ethics Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.